Market Cap

CSL Limited Market Capitalization:

A$136.95 Billion

AUD as of Jan. 1, 2023

US$93.24 Billion

business CSL Limited Company Profile

CSL Limited Main Stock Listing

show_chart ASX: CSL

Market Capitalization History of CSL Limited

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Biotechnology
Company Market Cap (USD)
Novo Nordisk $304.61 B
Regeneron Pharmaceuticals, Inc. $79.53 B
Marinomed Biotech AG $76.72 B
Vertex Pharmaceuticals Incorporated $74.13 B
Moderna, Inc. $68.42 B
Sector: Healthcare
Company Market Cap (USD)
UnitedHealth Group $495.37 B
Johnson & Johnson $461.85 B
Lilly $347.61 B
Novo Nordisk $304.61 B
Pfizer $287.63 B

Yearly evolution of CSL Limited market cap

Date Market Cap YoY Change
Jan. 1, 2023 A$136.95 B 9.08%
Jan. 1, 2022 A$125.54 B -0.85%
Jan. 31, 2021 A$126.63 B -5.56%
Jan. 1, 2021 A$134.08 B -10.14%
Jan. 31, 2020 A$149.22 B -0.84%
Jan. 1, 2020 A$150.48 B 61.05%
Jan. 31, 2019 A$93.43 B -0.35%
Jan. 1, 2019 A$93.76 B 19.16%
Jan. 31, 2018 A$78.68 B 11.75%
Jan. 1, 2018 A$70.41 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

Company Description

CSL Limited is a biotechnology company providing products to treat and prevent serious human medical conditions. CSL is involved in the research, development, manufacturing, and marketing of a wide range of products including blood plasma derivatives, vaccines, antivenom, and cell culture reagents for medical and genetic research and manufacturing applications.

business CSL Limited Company Profile

CSL Limited Categories

Australia languages Healthcare languages Biotechnology
Australia Healthcare Australia Biotechnology

Stocks & Indices

CSL Limited has the following listings and related stock indices.


Stock: ASX: CSL

Stock: FSX: CSJ

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.